Metropolitan Life Insurance Company (MetLife)’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,867	Closed	-$367K	–	2497
2022 Q4	$367K	Buy	1,867 +96	+5%	+$20.6K	0.02%	532
2022 Q3	$398K	Buy	1,771 +185	+12%	+$37.4K	0.02%	515
2022 Q2	$201K	Buy	1,586 +182	+13%	+$20.9K	0.01%	693
2022 Q1	$178K	Sell	1,404 -4,339	-76%	-$489K	0.01%	875
2021 Q4	$752K	Sell	5,743 -384	-6%	-$49.6K	0.01%	1149
2021 Q3	$750K	Buy	+6,127	New	+$707K	0.01%	1170
2021 Q2	–	Sell	-4,499	Closed	-$541K	–	2912
2021 Q1	$541K	Sell	4,499 -276	-6%	-$31.3K	0.01%	1363
2020 Q4	$485K	Hold	4,775	–	–	0.01%	1368
2020 Q3	$369K	Hold	4,775	–	–	0.01%	1413
2020 Q2	$532K	Buy	4,775 +1,497	+46%	+$130K	0.01%	1157
2020 Q1	$236K	Buy	3,278 +1,652	+102%	+$141K	﹤0.01%	1501
2019 Q4	$123K	Buy	+1,626	New	+$71.2K	﹤0.01%	2209

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s KRTX Position: Q1 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2023, closing a stake of 1,867 shares — an estimated $367K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in KRTX in Q4 2019 and held it in 12 quarters. The position peaked at $752K in Q4 2021. 246 funds tracked by Wall St. Rank hold KRTX as of Q1 2023.

Metropolitan Life Insurance Company (MetLife) reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 1,867 Karuna Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $367K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 12 quarters.
Metropolitan Life Insurance Company (MetLife)'s Karuna Therapeutics, Inc. Common Stock position peaked at $752K in Q4 2021.
246 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2023, filed 15 May 2023.